Przemyslaw Holko
Overview
Explore the profile of Przemyslaw Holko including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
27
Citations
145
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Jakubowski S, Holko P, Nowak R, Warmuth M, Dooms M, Salminen O, et al.
Front Pharmacol
. 2024 Dec;
15:1498386.
PMID: 39629081
Objectives: The aim of the study was to assess the reimbursement policy for orphan drugs (ODs) in selected European countries in relation to the availability and impact of clinical evidence,...
2.
Piorecka B, Holko P, Olesiak W, Sekulak K, Cichocka-Mroczek E, Stapor D, et al.
Nutrients
. 2024 Nov;
16(21).
PMID: 39519495
Background/objectives: Socioeconomic status and parental lifestyle influence dietary behaviors, including the administration of oral dietary supplements in children. The aim of this study was to evaluate the effects of selected...
3.
Mocko P, Koperny M, Sladowska K, Holko P, Kowalska-Bobko I, Kawalec P
Pharmacotherapy
. 2024 Sep;
44(10):811-821.
PMID: 39320112
Ulcerative colitis (UC) is a serious health problem that requires a constant need to identify new effective drugs. The aim of this study was to assess the efficacy and safety...
4.
Piorecka B, Koziol-Kozakowska A, Holko P, Kowalska-Bobko I, Kawalec P
Front Nutr
. 2024 Mar;
11:1341062.
PMID: 38524853
Background: A specialized diet could be due to an allergy or other medical needs and also religious or cultural reasons. This study aimed to assess the availability and provision of...
5.
Jakubowski S, Kawalec P, Holko P, Kowalska-Bobko I, Kamusheva M, Petrova G, et al.
Front Pharmacol
. 2024 Mar;
15:1369178.
PMID: 38523639
The aim of this study was to characterize the reimbursement policy for orphan drugs (ODs) in Central and Eastern European (CEE) countries in relation to the availability and impact of...
6.
Krawczyk K, Sladowska K, Holko P, Kawalec P
Front Pharmacol
. 2023 Sep;
14:1223929.
PMID: 37745049
This study aimed to compare the safety profile of tyrosine kinase inhibitors (TKIs) approved for use as monotherapy or combination therapy for the first-line treatment of adult patients with metastatic...
7.
Holko P, Kawalec P, Sajak-Szczerba M, Avedano L, Mossakowska M
Eur J Health Econ
. 2022 Oct;
24(7):1073-1083.
PMID: 36261612
Background: There is a high variability of out-of-packet patient costs of inflammatory bowel diseases (IBDs), but the issue is not widely recognised. Therefore, we compared patient costs of IBDs between...
8.
Holko P, Kawalec P, Sajak-Szczerba M, Avedano L, Mossakowska M
Inflamm Bowel Dis
. 2022 Jul;
29(5):752-762.
PMID: 35792501
Background: National studies report a high variability of indirect costs of inflammatory bowel disease (IBD). In this study, selected aspects of the societal burden of IBDs were compared between 12...
9.
Sladowska K, Kawalec P, Holko P, Osiecka O
Neurol Sci
. 2022 Jun;
43(9):5479-5500.
PMID: 35713731
Objective: This study aimed to compare the safety profile of high-efficacy disease-modifying therapies (DMTs) natalizumab, fingolimod, alemtuzumab, cladribine, ocrelizumab, ofatumumab, ozanimod, as well as a potentially high-efficacy DMT, ponesimod, in...
10.
Effectiveness of fixed-dose combination therapy in hypertension: systematic review and meta-analysis
Kawalec P, Holko P, Gawin M, Pilc A
Arch Med Sci
. 2018 Aug;
14(5):1125-1136.
PMID: 30154897
Introduction: Clinical studies have revealed that fixed-dose combinations (FDCs) of drugs can have a better effect on blood pressure than free-equivalent combinations (FECs). Our objectives were to perform an up-to-date...